News and features
Read the latest news and features about our world-leading research, discoveries, fundraising and philanthropy. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
Study unravels the genetics of childhood ‘overgrowth’
Researchers have undertaken the world’s largest genetic study of childhood overgrowth syndromes – providing new insights into their causes and new recommendations for genetic testing.
New blood test predicts who will benefit from targeted prostate cancer treatments
A new blood test could predict which men with advanced prostate cancer will respond to new targeted treatments for the disease.
How our 26 dedicated London Marathon 2017 runners are set to raise over £90,000 for cancer research
With donations to our dedicated #teamICR London Marathon runners set to top £90,000, Laura Mulkerne looks back on a day of gruelling effort, raucous support and hard-won medals.
ICR and Sutton Council call for improved transport infrastructure as Minister for London visits The London Cancer Hub
The Minister for London, Gavin Barwell MP, heard calls for improved public transport in Sutton on a visit to The London Cancer Hub.
Experimental drug could lead to potent combination in breast and other cancers
An experimental drug could be used in combination with chemotherapy as a treatment for breast and other cancers, new research shows.
Scientists identify new way of attacking breast cancer
Scientists have discovered a brand new way of attacking breast cancer that could lead to a new generation of drugs.
Weekly radiotherapy suitable for bladder cancer patients too frail for aggressive treatment, study finds
Older patients with bladder cancer who are too frail for aggressive treatment could benefit from weekly image-guided radiotherapy, new research reports.
-content.tmb-hbmobile.jpg?Culture=en&sfvrsn=fec93f9d_2 "Dispensing medicines for a clinical trial (Jan Chlebik for the ICR, 2014) content")
Nivolumab not recommended for relapsed or metastatic head-and-neck cancer on the NHS
The immunotherapy nivolumab will not be recommended for the treatment of patients with relapsed or metastatic head-and-cancer, under a new draft technology appraisal issued by NICE.
ICR ranked among top five in the world for university research
The Institute of Cancer Research, London, has ranked in the top five higher education institutions in the world for research in a new independent evaluation funded by the European Commission.
Drug makes head-and-neck cancer more sensitive to radiotherapy
A drug that has shown promise in breast and lung cancer trials also makes the combination of chemotherapy and radiotherapy more successful at killing head-and-neck cancers, a new study has found.
Find out why our supporter Jennifer is running the London Marathon for #teamICR
It’s nearly that time of year again, when runners from all over the world lace up their trainers and tackle one of the most famous marathons there is: the Virgin Money London Marathon. But why do our supporters do it? Heather Lacey caught up with one of our supporters, Jennifer Herbert, to find out why she decided to support our vital work by running 26.2 gruelling miles.
Prostate cancer drug combination shows promise in early trial
A combination of two drugs for prostate cancer is safe and shows signs of effectiveness in patients with advanced, aggressive disease, an early-stage trial reports.
